Hepatitis

A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…

A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…

A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…

Babies born extremely prematurely who were given a dose of the hepatitis B virus (HBV) vaccine within a day of being born were not…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…

Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…

Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…

Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…

A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to sustained clearance of the…

A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would start treatment — and ultimately…